Andrea F. Wainer
Ms. Wainer is a seasoned healthcare industry business leader with nearly 30 years of experience. Her expertise includes leading multinational businesses in unique environments with a focus on accelerated growth and business strategy to drive long-term sustainability.
Ms. Wainer served as Executive Vice President, Rapid and Molecular Diagnostics, at Abbott Laboratories (Abbott) from 2019 through February 2025. In this role, she led three innovative businesses across a global footprint: one focused on molecular diagnostics and the analysis of DNA and RNA at the molecular level, the second a provider of rapid point-of-care diagnostics, and the third delivers a leading hand-held point-of-care-device. Each of these offers products that provide clinicians with actionable information that can contribute to better clinical, operational and economic outcomes.
During her tenure, she led the Rapid and Molecular Diagnostics business in the development, manufacturing, and management of the leading COVID-19 testing business and delivered on innovation, bringing to market a number of products that save and improve lives.
Ms. Wainer joined Abbott in 1997 and served in a variety of roles within the company’s pharmaceuticals business, including divisional vice president and general manager, renal care. She also led the Animal Health business, and served as President, Molecular Diagnostics before taking on leadership of the Rapid and Molecular Diagnostics portfolio.
In addition to ADI, Ms. Wainer currently serves on the Board of Directors of Neogen Corporation. She also serves as a member of the Board of Trustees of the Goodman Theatre, Chicago, IL.
Ms. Wainer earned her bachelor’s degree in accounting from the John M. Olin School of Business, Washington University, St. Louis, Missouri, and her Masters in Business Administration from the Kellogg School of Management, Northwestern University in Evanston, Illinois.